The aforementioned data can be used to support the off-label use of dacomitinib or afatinib in selected EGFR TKI-naïve cases of advanced lung cancers harboring EGFR exon 20 insertion mutations with a G770 equivalent change. This evidence concerns the gene EGFR and lung carcinoma.